Glenmark receives FDA approval for generic BenzaClin gel
Glenmark Pharmaceuticals has received the Food and Drug Administration’s blessing for generic BenzaClin (clindamycin and benzoyl peroxide) gel 1%/5%.
The product, which is an acne treatment, is a generic of Valeant Bermuda’s branded product.
BenzaClin gel 1%/5% had a market value of approximately $99.4 million for the 12 month period ended January 2019, according to IQVIA.
No comments found